

Nabriva Therapeutics
267 posts











🚨Our February issue is LIVE🚨 We're getting ready for #pharma’s next chapter with our CEO #roundtablediscussion 🔷What's up in #biotech these days?🔷A conversation about the ethics of #antibiotics 🔷Plus so much more right here➡️ow.ly/5pHp50HRGYk #pharma #lifesciences



NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria. #GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: hubs.li/Q012sG-t0 #AMRSOS





Amid rising concerns over antibiotic resistance, the U.S. Department of Health and Human Services is moving to encourage Congress to create a novel incentive program for drug companies to develop these life-saving medicines. buff.ly/3ISYPx5

#AMR occurs when bacteria, viruses, fungi & parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of death. During #WAAW2021 learn how you can "Spread Awareness, Stop Resistance" bit.ly/2XvxSMY




This #WorldPneumoniaDay, NPs are encouraged to answer the call for #antibioticstewardship to help curb the leading cause of hospitalizations in the U.S. — community-acquired pneumonia. Learn more: bit.ly/3c6ScrL #NPweek #NPsLead


Opinion: The market for new antibiotics is so broken that even drugs and approaches with more specificity and better safety profiles can't turn a profit, all but destroying incentives for companies to invest in this area. buff.ly/3nBxg1v
